Designing Longevity
Skip to main content

Bone health and care options

Bone health, osteoporosis and fracture risk

Explore bone-risk assessment, condition-specific peptide medicines and questions to bring to a clinician. Keep the goal of reducing fractures separate from general longevity marketing, and read each treatment's exact population and evidence limits.

By Designing Longevity Editorial · Sources reviewed November 3, 2026 · How we work

Bone risk depends on your situation

Osteoporosis care is about bone strength and preventing fractures, not an anti-aging score. Screening recommendations have a defined scope. The U.S. Preventive Services Task Force recommends osteoporosis screening for women 65 and older and for postmenopausal women under 65 who are at increased risk. It says evidence is insufficient to assess the balance of benefits and harms of screening men. That is not a recommendation against screening men. The recommendation also does not cover people with known osteoporosis, prior fragility fractures, certain secondary causes or long-term use of some bone-loss medicines. Ask a clinician which guidance applies to your history.

Sources: [1]

Assessment comes before choosing a treatment

A bone-health visit can consider your fracture history, risk factors, medicines, other health conditions and any testing already done. Treatment decisions depend on the diagnosis and individual risk. This overview cannot decide whether you need a scan or a medicine, and it does not compare every osteoporosis treatment. Ask what the result means, which options fit your risk, what benefits are expected, and how treatment and follow-up will be monitored.

Sources: [1] [2]

Two peptide medicines have specific osteoporosis indications

FORTEO (teriparatide) is a parathyroid-hormone analog. Its label distinguishes osteoporosis treatment in high-risk postmenopausal women, increasing bone mass in men with primary or hypogonadal osteoporosis, and treatment of specified glucocorticoid-associated osteoporosis. The men's bone-mass indication is not the same endpoint as the women's fracture evidence. TYMLOS (abaloparatide) is a related peptide analog. Its label describes reducing vertebral and nonvertebral fractures in high-risk postmenopausal women; for high-risk men the indication is increasing bone density. These medicines have different warnings and duration instructions. Neither label establishes general rejuvenation or lifespan extension.

Sources: [3] [4]

Prescription treatment evidence

FORTEO and vertebral fracture evidence

Evidence of fewer new vertebral fractures seen on X-rays in postmenopausal women with osteoporosis at very high fracture risk, particularly those with prior vertebral fractures.

Evidence-of-benefit rating

4.5/5

This score describes the evidence for one benefit. It is not a treatment recommendation, a safety score, a price comparison, or a prediction for you. A clinician must assess whether this medicine is appropriate.

What the studies found

In the trial described in the FDA label, new vertebral fractures appeared on X-rays in 5.0% of evaluated women taking FORTEO plus calcium and vitamin D, compared with 14.3% taking placebo plus those supplements. Treatment lasted a median of 19 months. These group results are not a personal risk estimate.

A separate 24-month trial in women with severe osteoporosis found new vertebral fractures in 28 of 516 evaluated patients taking teriparatide versus 64 of 533 taking risedronate. Its clinical-fracture outcome also favored teriparatide. A third study supports the vertebral finding in a broader population.

Some participants did not have follow-up spine images. The studies had commercial sponsors; the third study used open-label teriparatide. X-ray fractures are not always symptomatic, and results do not establish a benefit at every fracture site.

Before considering treatment

FORTEO is a prescription medicine given by daily injection. Severe hypersensitivity is a contraindication. Other warnings include osteosarcoma risk factors, high blood calcium, kidney stones and dizziness on standing. Discuss your history, precautions and follow-on care with your clinician and read the full FDA label.

How this rating works

We use five fixed bands: 1.5, 2.5, 3.5, 4.5 and 5.0 out of 5. A 4.5 means direct studies support a meaningful benefit for the stated use after considering important uncertainties. It does not mean the treatment is best for you or that it is safer than other options.

Reviewed by Designing Longevity using source analysis and an independent AI critique. This assessment is not medically reviewed. Sources checked 2026-11-03 UTC.

Tell your clinician about conditions and medicines that affect bone care

The USPSTF screening statement excludes several groups, including people with secondary osteoporosis or long-term use of medicines associated with bone loss. That means the routine screening recommendation may not answer your case. A history of fracture, cancer, endocrine or kidney disease, or a medicine that can affect bone should be part of your care discussion. This page does not give an individualized screening schedule or prescribe a treatment.

Sources: [1] [3] [4]

Where to go next

Sources and dates

The source date describes the original material; the review date records our check. A dated source summary is not continuous monitoring, product testing or confirmation of current purchase terms.

  1. [1]U.S. Preventive Services Task Force: Osteoporosis to Prevent Fractures: Screening, Clinician Summary · Source date: January 14, 2025 · Reviewed

    Recommendation excludes secondary osteoporosis and chronic use of bone-loss-associated medicines, among other scope boundaries. Do not generalize this screening recommendation to diagnosis or treatment, or imply no clinician judgment for men.

  2. [2]CDC National Center for Injury Prevention and Control: CDC STEADI Algorithm for Fall Risk Screening, Assessment, and Intervention · Source date: 2019 resource; current PDF contents inspected, no newer date stated in document body · Reviewed

    This is a clinician-facing framework, not a validated self-diagnosis tool for all readers. No single screening score guarantees a person's fall risk or rules it out.

  3. [3]U.S. Food and Drug Administration: FORTEO (teriparatide) current U.S. prescribing information · Source date: Revised August 2026 · Reviewed

    Do not collapse the separate labeled populations or claim a general anti-aging, lifespan, or healthy-person benefit. Do not give prescribing or dosing advice from this summary; full contraindications, warnings, risks, treatment sequence and duration require label-context review. The label establishes the medicine's labeled indication, not a current seller, care plan, insurance coverage, or complete cost.

  4. [4]U.S. National Library of Medicine, DailyMed official label: TYMLOS (abaloparatide) current U.S. prescribing information · Source date: Revised August 2026 · Reviewed

    Keep population, endpoint and duration distinctions exact; do not imply the men's bone-density indication is the same fracture-outcome claim as for women. Do not infer general rejuvenation, lifespan benefit, comparison superiority, or retail/compounding legality. Label does not establish a current seller, care plan, insurance coverage, or complete cost.

Designing Longevity is a founder-led editorial publication. Our content is not medically reviewed.

See a problem or outdated information? Tell us.